company-header-background

GenVoy-ILM™

T Cell Kit for mRNA

Rethink Cell Therapy with Lipid Nanoparticles.


T-Cell Kit, Spark, Cartridge, Well Plate
Currently on the NanoAssemblr Spark
Rethink T Cell Gene Delivery
Lipid Nanoparticle (LNP) based technology enables researchers to establish a clinically relevant, scalable method for ex vivo gene delivery.

The GenVoy-ILM T Cell Kit for mRNA is an LNP reagent mix. It is optimized for the delivery of mRNA into activated primary human T cells using mRNA-LNPs formulated on the NanoAssemblr® Spark™ instrument and cartridges.  

 

This kit enables researchers to establish a clinically-relevant and scalable method for ex vivo gene delivery to advance the development of T cell therapies. It can be used at various stages of cell therapy research and development from discovery to preclinical across the NxGen™ microfluidics instrument platform.  

 

See the Data

The Advantages of the GenVoy-ILM T Cell Kit for mRNA

Engineered Cells

GREATER PROPORTION OF ENGINEERED CELLS

 

The GenVoy-ILM T Cell Kit for mRNA delivers mRNA into activated primary T cells consistently with high efficiency.

Engineered Cells

HIGH CELL VIABILITY

 

 

Nucleic acids delivered using the GenVoy-ILM T Cell Kit for mRNA are potent without causing cytotoxicity, resulting in highly viable cells that can be assayed in vitro and in vivo.

Tunable Protein Expression Icon

TUNABLE BIOLOGICAL OUTCOMES


Achieve an ideal balance between protein expression and cell viability in a dose-dependent manner. 
How the GenVoy-ILM T Cell Kit for mRNA Works
Preparing mRNA-LNPs from the GenVoy-ILM T Cell Kit for mRNA is quick and simple. One preparation takes under 5 minutes to prepare, and the resulting mRNA-LNPs can be seamlessly integrated into standard T cell culture workflows.

Get Started
To learn how Precision NanoSystems' GenVoy-ILM T Cell Kit for mRNA accelerates T cell therapy from an idea to clinical applications, contact our Scientific Specialists.
Get in Touch

Greater Proportion of Engineered T Cells

 

Delivering mRNA into activated human primary T cells using the GenVoy-ILM T Cell Kit for mRNA leads to a higher proportion of engineered T cells, making it a more potent gene delivery method than electroporation.

 

 

GFP
T Cell Graph Row 1 Graph 1
T Cell Graph Row 1 Graph 2
CD19 CAR
T Cell Graph Row 1 Graph 3
T Cell Graph Row 1 Graph 4
Transfection efficiency was measured by protein expression via flow cytometry at 24 and 48 hours post treatment. Electroporation (EP) was performed by following the manufacturer’s protocol, and LNP treatment was performed following the GenVoy-ILM T Cell Kit for mRNA on Spark™ protocol. Untreated cells (UT) were used as control. **p<0.01, ****p<0.0001 by one-way ANOVA 
Uniform Cellular Protein Expression

 

Engineering human primary T cells using the GenVoy-ILM T Cell Kit for mRNA results in highly uniform protein expression across the treated cell population. 

 

 

GFP
T Cell Histogram 1
T Cell Histogram 2
CD19 CAR
T Cell Histogram 2
T Cell Histogram 4
T Cell Histogram Legend
Representative mean fluorescence intensity (MFI) plots of cell surface protein expression were generated using flow cytometry at 24 and 48 hours post treatment. Electroporation was performed by following manufacturer’s protocol. Untreated cells (UT) were used as control.

Highly Viable T Cells

 

Activated human primary T cells remain highly viable after ex vivo gene delivery using the GenVoy-ILM T Cell Kit for mRNA.

 

 

GFP
Cell Viability Graph 2
Cell Viability Graph 1
CD19 CAR
Cell Viability Graph 4
Cell Viability Graph 3
Cell viability was measured via flow cytometry at 24 and 48 hours post treatment. Electroporation (EP) was performed by following the manufacturer’s protocol, and LNP treatment was performed following the T Cell Kit for mRNA on Spark™ protocol. Untreated cells (UT) were used as control. ****p<0.0001 by one-way ANOVA​ 
Tunable Biological Outcomes 

 

Achieve an ideal balance between transfection efficiency, protein expression, and cell viability in a dose-dependent manner.

 

 

Transfection Efficiency

Protein Expression Graph 1

Viability

 

Protein Expression Graph 1

Protein Expression

 

Protein Expression Graph 1
Protein Expression Graph 2

New Data Key

 

 

CD19 CAR transfection efficiency and cell viability were measured via flow cytometry 48 hours post treatment. Cells were treated with CD19 CAR mRNA at the indicated doses. Untreated cells (UT) were used as control. **p<0.01 by one-way ANOVA 
Functional Tumor Cell Killing

 

CAR T cells engineered using the GenVoy-ILM T Cell Kit for mRNA effectively kill CD19+ tumor cells in a dose-dependent manner.

 

 

NewData-Diagram
NewData-Diagram2
Tumor cell viability was assessed using flow cytometry. Lysis was determined by normalizing cell death in co-culture to controls. ***p<0.001, ****p<0.0001 by one-way ANOVA 

Easily Integrated into Standard T Cell Culture Protocols

 

A simpler workflow combined with minimal T cell manipulation enable higher cell viability.

 

T Cell Kit Workflow-Brochure (1)
T Cell Kit Workflow-Brochure EP

Related Instruments, Cartridges and Accessories

The GenVoy-ILM T Cell Kit for mRNA is optimized for the delivery of mRNA into activated primary human T cells using mRNA-LNPs formulated on the NanoAssemblr® Spark™ instrument and cartridges.
Start operating the Spark with little to no training. Formulations are ready in seconds. Plus, they can be made on-demand in a sterile hood for immediate cell culture application.
No cleaning or cleaning validation required: Cartridges are single-use and gamma irradiated for sterility. Available in packs of 20.
T Cell Kit Pipetting
Sign Up and Stay Informed
Sign up today to automatically receive new Cytiva, formerly Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up